| 13.74 0.08 (0.59%) | 10-04 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 17.77 | 1-year : | 19.27 |
| Resists | First : | 15.21 | Second : | 16.5 |
| Pivot price | 14.4  |
|||
| Supports | First : | 13.13 | Second : | 10.92 |
| MAs | MA(5) : | 13.92 |
MA(20) : | 14.41 |
| MA(100) : | 14.73  |
MA(250) : | 13.05 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 24.4 |
D(3) : | 29.6 |
| RSI | RSI(14): 44 |
|||
| 52-week | High : | 21.44 | Low : | 7.57 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ GLSI ] has closed above bottom band by 16.1%. Bollinger Bands are 25.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 14.08 - 14.14 | 14.14 - 14.2 |
| Low: | 13.23 - 13.31 | 13.31 - 13.37 |
| Close: | 13.62 - 13.74 | 13.74 - 13.85 |
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
Mon, 30 Sep 2024
Greenwich LifeSciences CEO buys $21,945 in company stock - Investing.com India
Mon, 30 Sep 2024
Insider Buying: Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Acquires 1,500 Shares of Stock - MarketBeat
Mon, 16 Sep 2024
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) VP Jaye Thompson Buys 800 Shares - MarketBeat
Wed, 26 Jun 2024
Greenwich LifeSciences Set to Join Russell 2000 Index Again - Yahoo Finance
Wed, 26 Jun 2024
Greenwich LifeSciences to join Russell indexes - Investing.com
Wed, 26 Jun 2024
Greenwich LifeSciences: Halting Of Breast Cancer Recurrence With GLSI-100 (NASDAQ:GLSI) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 13 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 52.9 (%) |
| Held by Institutions | 8.5 (%) |
| Shares Short | 505 (K) |
| Shares Short P.Month | 452 (K) |
| EPS | -0.8 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.44 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -72.5 % |
| Return on Equity (ttm) | -123.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.81 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -17.4 |
| PEG Ratio | 0 |
| Price to Book value | 30.53 |
| Price to Sales | 0 |
| Price to Cash Flow | -26.59 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|